-
An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021
-
Sarah V Williams1,*
, Amoolya Vusirikala1,*
, Shamez N Ladhani1 , Elena Fernandez Ruiz De Olano 2 , Nalini Iyanger2 , Felicity Aiano1 , Kelly Stoker1 , Guduru Gopal Rao3 , Laurence John3 , Bharat Patel1 , Nick Andrews1 , Gavin Dabrera1 , Mary Ramsay1 , Kevin E Brown1 , Jamie Lopez Bernal1 , Vanessa Saliba1
-
View Affiliations Hide AffiliationsAffiliations: 1 National Infection Service, Public Health England, London, United Kingdom 2 London Coronavirus Response Centre, Public Health England, London, United Kingdom 3 London North West University Healthcare NHS Trust, London, United Kingdom* These authors contributed equally to this work and share first authorship.Correspondence:Sarah V Williamssarah.v.williams phe.gov.uk
-
View Citation Hide Citation
Citation style for this article: Williams Sarah V, Vusirikala Amoolya, Ladhani Shamez N, Fernandez Ruiz De Olano Elena, Iyanger Nalini, Aiano Felicity, Stoker Kelly, Gopal Rao Guduru, John Laurence, Patel Bharat, Andrews Nick, Dabrera Gavin, Ramsay Mary, Brown Kevin E, Lopez Bernal Jamie, Saliba Vanessa. An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021. Euro Surveill. 2021;26(27):pii=2100626. https://doi.org/10.2807/1560-7917.ES.2021.26.27.2100626 Received: 22 Jun 2021; Accepted: 07 Jul 2021
Abstract
We investigated a COVID-19 outbreak of the SARS-CoV-2 Delta variant of concern in a London care home, where 8/21 residents and 14/21 staff had received a single dose of Vaxzevria (ChAdOx1-S; AstraZeneca) vaccine. We identified 24 SARS-CoV-2 infections (16 residents, 8 staff) among 40 individuals (19 residents, 21 staff); four (3 residents, 1 staff) were hospitalised, and none died. The attack rate after one vaccine dose was 35.7% (5/14) for staff and 81.3% (13/16) for residents.

Article metrics loading...

-
From This Site
/content/10.2807/1560-7917.ES.2021.26.27.2100626dcterms_title,dcterms_subject,pub_keyword-contentType:Journal -contentType:Contributor -contentType:Concept -contentType:Institution105 -
PubMed
-
Google Scholar

Full text loading...
References
-
Dunn P, Allen L, Cameron G, Malhotra AM, Alderwick H. COVID-19 policy tracker 2020. London: The Health Foundation; 2021. Available from: https://www.health.org.uk/news-and-comment/charts-and-infographics/covid-19-policy-tracker
-
National Health System Test and Trace. Care home COVID-19 testing guidance: for testing of staff and residents. London: United Kingdom Government; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/988099/Care_Home_Testing_Guidance_England_v12-03_rev4_DIGITAL.pdf
-
Public Health England (PHE). Evaluation of Roche Elecsys Anti-SARS-CoV-2 S serology assay for the detection of anti-SARS-CoV-2 S antibodies. London: PHE; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/989460/Evaluation_of_Roche_Elecsys_anti_SARS_CoV_2_S_assay_PHE.pdf
-
Public Health England (PHE). Evaluation of Roche Elecsys Anti-SARS-CoV-2 serology assay for the detection of anti-SARS-CoV-2 antibodies. London: PHE; 2020. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/891598/Evaluation_of_Roche_Elecsys_anti_SARS_CoV_2_PHE_200610_v8.1_FINAL.pdf
-
The Public Health England (PHE) Variant Technical Group. SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 10. London: PHE. [Accessed: 15 Jun 2021]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/984274/Variants_of_Concern_VOC_Technical_Briefing_10_England.pdf
-
Patel MC, Chaisson LH, Borgetti S, Burdsall D, Chugh RK, Hoff CR, et al. Asymptomatic SARS-CoV-2 infection and COVID-19 mortality during an outbreak investigation in a skilled nursing facility. Clin Infect Dis. 2020;71(11):2920-6. https://doi.org/10.1093/cid/ciaa763 PMID: 32548628
-
McMichael TM, Currie DW, Clark S, Pogosjans S, Kay M, Schwartz NG, et al. Epidemiology of Covid-19 in a long-term care facility in King County, Washington. N Engl J Med. 2020;382(21):2005-11. https://doi.org/10.1056/NEJMoa2005412 PMID: 32220208
-
Public Health England (PHE). COVID-19: the green book, chapter 14a. London, PHE. [Accessed: 11 Jun 2021]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/984310/Greenbook_chapter_14a_7May2021.pdf
-
United States Food and Drug Administration (FDA). Pfizer-BioNTech COVID-19 vaccine emergency use authorization review memorandum. Silver Spring: FDA; 2020. Available from: https://www.fda.gov/media/144416/download
-
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15. https://doi.org/10.1056/NEJMoa2034577 PMID: 33301246
-
Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881-91. https://doi.org/10.1016/S0140-6736(21)00432-3 PMID: 33617777
-
Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373(1088):n1088. https://doi.org/10.1136/bmj.n1088 PMID: 33985964
-
Vasileiou ESC, Simpson CR, Robertson C, Shi T, Kerr S, Agrawal U, et al. Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People. 2021. https://doi.org/DOI:10.2139/ssrn.3789264
-
Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study). medRxiv. 2021.03.26.21254391. https://doi.org/10.1101/2021.03.26.21254391
-
Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv. 2021:2021.05.22.21257658. https://doi.org/10.1101/2021.05.22.21257658
-
Stowe J, Andrews N, Gower C, Gallagher E, Utsi L, Simmons R, et al. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. London: Public Health England; 2021. Pre-print. Available from: https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view/479607266
-
Public Health England (PHE). Variants: distribution of case data, 11 June 2021. London: United Kingdom Government; 2021. Available from: https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-case-data-11-june-2021
-
Department of Health and Social Care. Adult social care monthly statistics, England: May 2021. London: United Kingdom Government; 2021. Available from: https://www.gov.uk/government/statistics/adult-social-care-in-england-monthly-statistics-may-2021/adult-social-care-monthly-statistics-england-may-2021

Data & Media loading...
